GlassScriptPhysician profile
Mary L Pine
NPI 1649388588
$4,346.61
in general payments reported to CMS, 2019-2025
25 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $817 · 2023: $817 · 2024: $820 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,158.29 | 2022-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.60 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $488.33 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $387.00 | 2021-2025 | |
| Novo Nordisk INC | $324.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $181.91 | 2023-2025 | |
| Abbvie INC. | $176.97 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $161.26 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.80 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $136.84 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $105.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.09 | 2024-2025 | |
| Kyowa Kirin, INC. | $51.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $47.77 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.96 | 2021-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Shield Therapeutics INC | $28.60 | 2024 | |
| Corium, LLC | $23.68 | 2023 | Azstarys |
| Indivior INC. | $21.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.69 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $20.41 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.68 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.16 | 2021 | |
| Daiichi Sankyo INC. | $17.02 | 2024 | Injectafer |
| Antares Pharma, INC. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Pine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.